Effects of Low Protein Diet Supplemented Keto-/Amino Acid in Preventing the Progression of Chronic Kidney Disease (CKD)- ELPD Study (ELPD-CKD)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether low protein diet and very low protein diet supplemented keto-/amino acid is effective in preventing the progression of chronic kidney disease (CKD , stage 3b and 4).
| Condition | Intervention |
|---|---|
|
Chronic Kidney Disease |
Behavioral: low protein diet plus α-keto acid Behavioral: very low protein diet plus α-keto acid |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effects of Low Protein Diet Supplemented Keto-/Amino Acid in Preventing the Progression of Chronic Kidney Disease(CKD)- ELPD Study |
- changes in glomerular filtration rate [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
- Compliance to diet [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Quality of life [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Cardiovascular morbidity [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]Cardiovascular morbidity, defined by angina, heart failure, myocardial infarction, left ventricular mass, stroke, blood pressure, lipid profile, calcium/phosphorus/parathormone status and Charlson comorbidity index, at the start of dialysis
- Nutritional status [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]Nutritional status, defined by anthropo-plicometry, biochemistry, body bioimpedance analysis (BIA), subjective global nutritional assessment (SGA), at the start and during the 1st year of dialysis
| Estimated Enrollment: | 120 |
| Study Start Date: | August 2011 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: low protein diet
Behavioral: low protein diet 0.6g of proteins per kilo of body weight per day
|
|
|
Experimental: low protein diet plusα-keto acid
0.6g of proteins per kilo of body weight per day
|
Behavioral: low protein diet plus α-keto acid
low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
|
|
Experimental: very low protein diet plus α-keto acid
0.3g of proteins per kilo of body weight per day
|
Behavioral: very low protein diet plus α-keto acid
very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
|
Detailed Description:
Dietary protein restriction represents a basic therapeutic approach in chronic kidney disease(CKD), by reducing the accumulation of nitrogen catabolic substances, and by delaying the progress of CKD and proteinuria, but the effects of the different degree's protein diet on the renal progression remain to be determined.
The aim of this study is to evaluate the efficacy of low protein diet and α-keto acid tablet in retard the progress of CKD. This is a randomized, open-label, prospective study, 120 patients who meet inclusion and exclusion criteria will be randomized into three groups at the ratio of 1:1:1. Group I patients will receive low protein diet(0.6g/kg BW), group II will receive low protein diet supplemented with α-keto acid, while group III will take very low protein diet(0.3g/kg BW) supplemented with α-keto acid. The changes of glomerular filtration rate in CKD will be evaluated after 1 year treatment.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with chronic kidney disease in stage 3b and 4(15ml/min/1.73m2<GFR<45 ml/min/1.73m2, estimated by EPI formula) receiving conservative treatment for CKD
Exclusion Criteria:
- With diagnosis of diabetic mellitus;
- Incapable of following study requirements to control diet;
- Glomerular filtration rate < 15 ml/min/1.73m2;
- Hypercalcemia or hyperkalemia (> normal upper limit);
- Other serious disease(eg.heart,lung,brain) within the last 3 months;
- Cardiac failure stage IV NYHA;
- With cirrhosis of liver or obvious symptoms of liver diseases, ALT or AST two times normal upper limit;
- Severe edema or serous cavity effusion;
- Drug abuse;
- Final diagnosis of malignant tumor;
- Receiving the long-term systematic steroid hormone or immunosuppressive agents(eg. Cyclophosphamidum,Cyclosporine, Prograf,Azathioprine) treatment;
- Gestation already, prepares to be pregnant in the period of the trial, lactating women;
- Participate in other product clinical trial within 30 days prior to this trial
Contacts and Locations| Contact: Xuemei Li, M.D.& Ph.D. | 8610-65295058 | 0605.mei@gmail.com |
| Contact: Limeng Chen, M.D.& Ph.D. | 8610-65295351 | climeng2000@yahoo.com.cn |
| China, Beijing | |
| Peking Union Medical College Hospital | Recruiting |
| Beijing, Beijing, China, 100730 | |
| Contact: Xuemei Li, M.D.& Ph.D. 8610-65295058 0605.mei@gmail.com | |
| Contact: Limeng Chen, M.D.& Ph.D. 8610-65295351 climeng2000@yahoo.com.cn | |
| Principal Investigator: | Xuemei Li, M.D.& Ph.D. | Peking Union Medical College Hospital |
More Information
No publications provided
| Responsible Party: | Xuemei Li, department of nephrology |
| ClinicalTrials.gov Identifier: | NCT01418508 History of Changes |
| Other Study ID Numbers: | ELPD-CKD |
| Study First Received: | August 15, 2011 |
| Last Updated: | August 16, 2011 |
| Health Authority: | China: Ministry of Health |
Additional relevant MeSH terms:
|
Kidney Diseases Renal Insufficiency, Chronic Kidney Failure, Chronic Urologic Diseases Renal Insufficiency |
ClinicalTrials.gov processed this record on May 22, 2013